Article thumbnail

Efficacy and complications of neurosurgical treatment of acromegaly

By Anna Krzentowska-Korek, Filip Gołkowski, Agata Bałdys-Waligórska and Alicja Hubalewska-Dydejczyk

Abstract

The aim of the study was to evaluate the frequency of occurrence of pituitary failure following neurosurgery and the efficacy of transsphenoidal tumour resection in acromegalic patients. We retrospectively evaluated 85 patients (60 female and 25 male), of mean age 43.9 ± 13.2 years, treated by transsphenoidal neurosurgery. Macroadenoma and microadenoma of pituitary were found in 66 (77.6%) and 19 (22.4%) of these patients, respectively. Criteria of cure following neurosurgery were: basal GH < 2.5 μg/l, GH at 120 min in OGTT < 1.0 μg/l and serum concentration of IGF-1 within normal ranges for age and sex. After surgery 32 patients (37.6%) were cured and 53 patients (62.4%) required somatostatin analogue treatment. In patients cured by surgery, lower levels of basal GH (P < 0.05), IGF-1 (P < 0.001), GH at 120 min in OGTT and smaller size of pituitary tumour (P < 0.05) were found at diagnosis, as compared to patients in whom surgery was unsuccessful. Significant correlation between basal serum level of GH at diagnosis and size of pituitary tumour was found (P < 0.001). Invasive tumours were found in 45 of 53 (84.9%) patients not cured and in only 8 of 32 (25.0%) patients cured (P < 0.001). Impaired function of pituitary anterior lobe after surgery was observed in 30% and 4% of patients with macro- and microadenoma, respectively (P < 0.05). The efficacy of neurosurgery is affected by concentration of basal serum GH and IGF-1, GH at 120 min in OGTT, tumour size and invasiveness. Hypopituitarism after surgery is more frequent in patients with macroadenoma. Pituitary insufficiency, as a consequence of surgery, was found in 21% of patients with normal pituitary function prior to operation

Topics: Article
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:3094540
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Acromegaly: rethinking the cancer risk. Rev Endocrinol Metab Disord 9:41–58
  2. (2001). Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group.
  3. (2006). Cancers associated with acromegaly.
  4. Casaneuva FF, Cavagnini F et al (2002) Consensus. Guidelines for acromegaly management.
  5. Casanueva FF et al (2000) Criteria for cure of acromegaly: a consensus statement.
  6. (2001). Clinical perspective: acromegaly and cancer: a problem.
  7. (1997). Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.
  8. (2010). Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve.
  9. (2004). Epidemiology clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espan ˇol de Acromegalia,
  10. (1999). Epidemiology of acromegaly.
  11. (2004). Factors influencing mortality in acromegaly.
  12. (1997). Factors predicting pituitary adenoma invasiveness in acromegalic patients.
  13. (1998). Long-term endocrinologic follow-up after transsphenoidal surgery for acromegaly.
  14. (1998). Longterm mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.
  15. (1998). Mortality and cancer incidence in acromegaly; a retrospective cohort study. United Kingdom acromegaly study group.
  16. (1990). Premature mortality due to cardiovascular disease in hypopituitarism.
  17. (1999). Prognostic factors in the surgical management of acromegaly.
  18. (2010). Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
  19. (2008). Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.
  20. SheppardMC,HawkinsMM,BatesAS,StewartPM(2009)ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.
  21. (2004). Systemic complications of acromegaly: epidemiology, pathogenesis and management.
  22. (2005). The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘‘cure’’.
  23. (2006). Transsphenoidal microsurgery for newly diagnosed acromegaly: A personal view after more than 1,000 operations.
  24. (2003). Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume.